| RBRC No. | RBRC02414 |
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type | Targeted Mutation |
 |
||||||||||||||||||||||||||||||
| Species | Mus musculus | |||||||||||||||||||||||||||||||
| Strain name | A/J.Cg-Nfe2l2<tm1Mym> | |||||||||||||||||||||||||||||||
| Former Common name | Nrf2 knock out mouse (A/J background) | |||||||||||||||||||||||||||||||
| H-2 Haplotype | No Data | |||||||||||||||||||||||||||||||
| Background strain | A | |||||||||||||||||||||||||||||||
| Appearance | ||||||||||||||||||||||||||||||||
| 1 | Appearance | albino | ||||||||||||||||||||||||||||||
| Genotype | a/a b/b c/c | |||||||||||||||||||||||||||||||
| Strain development | Developed by Masayuki Yamamoto, Institute of Basic Medical Sciences and Center for Tsukuba Advanced Research Alliance, University of Tsukuba in 1996. The targeting vector containing lacZ-neo cassette was transferred into E14 ES cells to replace the 1.2 kb segment containing the rest of the exon 5 coding sequence of the Nrf2 gene. | |||||||||||||||||||||||||||||||
| Strain description | Nrf2 (Nfe2l2) Knockout mice. This strain is a useful model for the in vivo analysis of chemical carcinogenesis and resistance to anti-cancer drugs. A phenolic antioxidant significantly induced the expression of phase II enzymes such as glutathione S-transferase and NAD(P)H: quinone oxidoreductase in normal mice. However, in the homozygous Nrf2 deficient mice the induction of the phase II enzymes by a phenolic antioxidant was largely eliminated in the liver and intestine. Since Nrf2 is constantly degraded by proteasome under normal condition, it is hardly to detect Nrf2 protein in the absence of stimuli. Electrophilic chemicals, such as DEM (diethyl maleate) and tBHQ (tert-buthyl hydroquinone), are generally used to stabilize Nrf2. Or proteasomal inhibitors, such as MG132, are also effective increasing the protein amount of Nrf2. C57BL/6 background (RBRC01390), BALB/c background (RBRC02190), A/J background (RBRC02414), ICR mixed background (RBRC00984). Homozygous mutant mice are viable and fertile, but show lower reproductive performance. | |||||||||||||||||||||||||||||||
| Colony maintenance | Homozygote x Heterozygote [or Crossing to A/JJmsSlc] | |||||||||||||||||||||||||||||||
| Health Report |
BRC facility Health Report in the last year and a half
|
|||||||||||||||||||||||||||||||
| Gene Details | ||||||||||||||||||||||||||||||||
| Promoter | No Data | |||||||||||||||||||||||||||||||
| 1 | Symbol | Nfe2l2 | ||||||||||||||||||||||||||||||
| Symbol name | nuclear factor, erythroid derived 2, like 2 | |||||||||||||||||||||||||||||||
| Chromosome | 2 | |||||||||||||||||||||||||||||||
| Common name | Nrf2 | |||||||||||||||||||||||||||||||
| Symbol description | No Data | |||||||||||||||||||||||||||||||
| 2 | Symbol | lacZ | ||||||||||||||||||||||||||||||
| Symbol name | beta-galactosidase (E. coli) | |||||||||||||||||||||||||||||||
| Chromosome | 2 | |||||||||||||||||||||||||||||||
| Common name | No Data | |||||||||||||||||||||||||||||||
| Symbol description | E. coli beta galactosidase | |||||||||||||||||||||||||||||||
| 3 | Symbol | nls | ||||||||||||||||||||||||||||||
| Symbol name | SV40 large T antigen nuclear localization signal (NLS) | |||||||||||||||||||||||||||||||
| Chromosome | 2 | |||||||||||||||||||||||||||||||
| Common name | No Data | |||||||||||||||||||||||||||||||
| Symbol description | No Data | |||||||||||||||||||||||||||||||
| Promoter | herpes simplex virus thymidine kinase promoter (HSV tk promoter) | |||||||||||||||||||||||||||||||
| 4 | Symbol | neo | ||||||||||||||||||||||||||||||
| Symbol name | neomycin resistance gene (E. coli) | |||||||||||||||||||||||||||||||
| Chromosome | 2 | |||||||||||||||||||||||||||||||
| Common name | neo; neomycin; | |||||||||||||||||||||||||||||||
| Symbol description | No Data | |||||||||||||||||||||||||||||||
| References | Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22.
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.
|
|||||||||||||||||||||||||||||||
| Research applications | Cancer Research, Cell Biology Research, Metabolism Research |
|||||||||||||||||||||||||||||||
| Specific Term and Conditions | The following terms and conditions will be requested by the DEPOSITOR. The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Biochem. Biophys. Res. Commun., 236, 313-322 (1997). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. After deposition of the BIOLOGICAL RESOURCE, two years are assumed to be a collaborative research with the DEPOSITOR. The DEPOSITOR maintains the patent and the intellectual property right of the BIOLOGICAL RESOURCE. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. |
|||||||||||||||||||||||||||||||
| Additional information | ||||||||||||||||||||||||||||||||
| 1 | Lab HP (Japanese) | |||||||||||||||||||||||||||||||
| 2 | Mouse of the Month Apr 2012 | |||||||||||||||||||||||||||||||
| 3 | Genotyping protocol <PCR> | |||||||||||||||||||||||||||||||
| Depositor | Yamamoto, Masayuki (University of tsukuba)  |
|||||||||||||||||||||||||||||||
| Strain Status / Availability (Expected delivery) |
|
|||||||||||||||||||||||||||||||
